Sarepta Therapeutics (NASDAQ: SRPT) recently received a number of ratings updates from brokerages and research firms:

  • 10/3/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $64.00 price target on the stock.
  • 10/2/2017 – Sarepta Therapeutics was upgraded by analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating. They now have a $60.00 price target on the stock.
  • 10/2/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $101.00 price target on the stock.
  • 10/2/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Credit Suisse Group. They now have a $81.00 price target on the stock.
  • 10/2/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Instinet. They now have a $84.00 price target on the stock.
  • 10/2/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
  • 10/2/2017 – Sarepta Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/30/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $66.00 price target on the stock.
  • 9/25/2017 – Sarepta Therapeutics had its “hold” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 9/25/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/15/2017 – Sarepta Therapeutics is now covered by analysts at Royal Bank Of Canada. They set a “positive” rating on the stock.
  • 9/14/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $69.00 price target on the stock.
  • 9/7/2017 – Sarepta Therapeutics had its price target raised by analysts at Credit Suisse Group from $5.65 to $81.00. They now have an “outperform” rating on the stock.
  • 9/7/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $76.00 price target on the stock.
  • 9/7/2017 – Sarepta Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $55.00 price target on the stock, up previously from $50.00.
  • 9/7/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
  • 9/7/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $56.00 price target on the stock.
  • 9/6/2017 – Sarepta Therapeutics had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $101.00 price target on the stock.
  • 9/6/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $75.00 price target on the stock.
  • 9/6/2017 – Sarepta Therapeutics is now covered by analysts at Barclays PLC. They set an “equal weight” rating and a $46.00 price target on the stock.
  • 9/5/2017 – Sarepta Therapeutics had its “buy” rating reaffirmed by analysts at Nomura. They now have a $84.00 price target on the stock.
  • 8/4/2017 – Sarepta Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

Sarepta Therapeutics Inc (NASDAQ SRPT) opened at 49.55 on Tuesday. The stock’s market cap is $3.19 billion. Sarepta Therapeutics Inc has a 12-month low of $26.26 and a 12-month high of $63.03. The firm’s 50-day moving average price is $42.14 and its 200 day moving average price is $35.85.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.46. Sarepta Therapeutics had a negative net margin of 180.07% and a negative return on equity of 62.68%. The company had revenue of $35.01 million for the quarter, compared to analysts’ expectations of $22.52 million. During the same quarter in the previous year, the company posted ($1.19) EPS. The firm’s quarterly revenue was up 350000.0% on a year-over-year basis. Analysts anticipate that Sarepta Therapeutics Inc will post ($1.22) EPS for the current year.

In other Sarepta Therapeutics news, CEO Douglas S. Ingram acquired 47,058 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The stock was bought at an average price of $42.50 per share, with a total value of $1,999,965.00. Following the purchase, the chief executive officer now owns 382,058 shares in the company, valued at $16,237,465. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at approximately $934,513. The disclosure for this sale can be found here. Over the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. Insiders own 9.60% of the company’s stock.

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Stock Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related stocks with our FREE daily email newsletter.